DUBLIN – DBV Technologies SA reported further progress from its patch-based peanut allergy therapy, Viaskin Peanut, at the American Academy of Allergy, Asthma and Immunology (AAAAI) congress in Los Angeles over the weekend, including 52-week data from a phase II trial conducted by the Consortium of Food Allergy Research (Cofar) and sponsored by the National Institute of Allergy and Infectious Disease.